Sclerosing Agent Shortage Begins

The US Food and Drug Administration (FDA) has declared the beginning of a shortage of Sclerosol 4 GM (NDC 63256-100-30), a treatment applied to the skin of patients who have breathing problems caused by a buildup of fluid, possibly from conditions such as mesothelioma.

________________________________________________________________________________
RELATED CONTENT
Two Maintenance Inhalers for Asthma Approved
One-Third of Adults With Recent Asthma Diagnosis Do Not Have Asthma
________________________________________________________________________________

The drug is produced by Lymol Medical Corp; the FDA has not yet given a reason for the shortage and have no timetable for when it will be available.

Pharmacy Learning Network will provide an update when we have more information.—Sean McGuire